Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib for SARS-Cov-2 Induced Pulmonary Fibrosis
NCT04541680Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2020
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis (PF) comparing Nintedanib Arm with Placebo Arm (2 arms). Primary endpoint: Decline in Forced Vital Capacity at 12 months. Started Oct 2020; status: recruiting.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT04541680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541680.